Dextromethorphan

證據等級: L5

預測適應症: 6 個

Dextromethorphan: From Antitussive to Nasal Cavity Disease

One-Sentence Summary

Dextromethorphan (DXM) is a widely used over-the-counter cough suppressant that acts on the medullary cough center, commonly found in cold and flu preparations worldwide. The TxGNN model predicts it may be effective for Nasal Cavity Disease, with 1 Phase 3 clinical trial identified in the evidence search — though that trial targets Major Depressive Disorder rather than nasal cavity disease directly — and no published literature currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Antitussive (cough suppression)
Predicted New Indication	Nasal Cavity Disease
TxGNN Prediction Score	99.98%
Evidence Level	L2 (1 Phase 3 trial identified; note: trial targets MDD, not nasal cavity disease directly)
Taiwan Market Status	✗ Not marketed
Number of Approvals	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action (MOA) data is not available in this evidence pack. Based on established pharmacological knowledge, DXM is a low-affinity NMDA receptor antagonist and sigma-1 receptor agonist acting at the medullary cough center. It suppresses the cough reflex centrally, which is why it has been used as a first-line antitussive for decades.

The connection to nasal cavity disease is mechanistically coherent: nasal conditions such as allergic rhinitis and chronic sinusitis frequently drive postnasal drip-induced cough and airway hypersensitivity. DXM’s suppression of the cough reflex arc directly addresses one of the most bothersome downstream symptoms of nasal cavity disease. Additionally, sigma-1 receptor agonism may inhibit release of neurogenic pro-inflammatory mediators (such as substance P and CGRP) at upper airway mucosal nerve terminals, offering a secondary anti-neuroinflammatory effect.

In this sense, the TxGNN prediction is not a radical leap — nasal cavity disease and antitussive therapy share overlapping pathophysiology. However, it is important to distinguish between treating a symptom of nasal disease (cough) and treating the nasal cavity disease itself. Whether DXM provides benefit beyond cough relief — for example, reducing mucosal inflammation, improving nasal patency, or altering disease course — remains unproven and requires direct clinical investigation.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06958692	Phase 3	Recruiting	388	Multicenter, randomized, double-blind, placebo-controlled trial evaluating DXM + bupropion sustained-release tablets in Chinese adult patients with Major Depressive Disorder. ⚠️ This trial targets MDD, not nasal cavity disease — the match was based on DXM as the active agent, not the disease indication. Results not yet available (expected completion: December 2026).

⚠️ Evidence Caveat: The single identified trial (NCT06958692) investigates a DXM/bupropion combination for Major Depressive Disorder. It does not directly assess nasal cavity disease. The evidence level L2 designation reflects the trial’s Phase 3 design quality, but the clinical relevance to nasal cavity disease is indirect at best. No trials directly studying DXM for nasal cavity disease were found.

Literature Evidence

Currently no related literature available for Dextromethorphan × Nasal Cavity Disease.

Taiwan Market Information

Dextromethorphan currently has no approved products registered with the Taiwan FDA (TFDA). No license data is available.

Note: DXM is widely approved internationally as an OTC antitussive (e.g., in the US, EU, Japan, and many other markets). The absence of a Taiwan registration does not reflect global regulatory status.

Safety Considerations

Please refer to the package insert for safety information.

Safety data (key warnings, contraindications, and drug-drug interactions) were not retrievable for this evidence pack. Given that DXM is known to interact with MAO inhibitors, serotonergic agents, and CYP2D6 substrates, a thorough safety review is essential before any clinical development proceeds.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic basis for DXM in nasal cavity disease is plausible — its antitussive mechanism directly addresses a primary symptom of nasal conditions — but no direct clinical evidence exists, and the single Phase 3 trial identified targets MDD rather than any nasal indication. The TxGNN score is high (99.98%), suggesting strong graph-based structural similarity, but this likely reflects the shared upper respiratory disease topology in the knowledge graph rather than direct pharmacological validation.

To proceed, the following is needed:

Targeted clinical trial search: Re-query ClinicalTrials.gov and ICTRP specifically for DXM in rhinitis, sinusitis, or postnasal drip with broader search terms (e.g., “dextromethorphan rhinitis,” “DXM postnasal drip”)
Literature gap closure: Conduct a systematic PubMed/Embase search for DXM in nasal or upper airway conditions; the current search returned zero results and may have used overly narrow MeSH terms
MOA documentation: Retrieve full DrugBank MOA entry (DG002 remediation) to support mechanistic write-up
Safety profile review: Download Taiwan package insert or FDA label (DG001 remediation) to assess contraindications and DDI risks — particularly MAO inhibitor interaction and serotonin syndrome risk
Proof-of-concept study design: If the above searches confirm no prior nasal cavity disease data, a small-scale PoC study (e.g., DXM vs. placebo in postnasal drip-associated cough secondary to chronic rhinitis) would be an appropriate next step before committing to a full Phase 2 design
Taiwan regulatory pathway: Since DXM is not marketed in Taiwan, a full regulatory strategy (IND + NDA) would be required, adding timeline and cost considerations
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.